Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Critical Care Medicine, Affiliated Hospital of Shaoxing University, Shaoxing, China.
Infect Dis (Lond). 2024 Feb;56(2):128-137. doi: 10.1080/23744235.2023.2276785. Epub 2023 Dec 18.
To evaluate the value of nanopore targeted sequencing in diagnosing pneumonia pathogens.
This large-scale multicentre prospective study performed in 8 hospitals across China from April to October 2022. Hospitalised patients with a diagnosis of pneumonia at admission were included. Complete clinical data were collected, and bronchoalveolar lavage fluid were obtained from each patient. These samples underwent simultaneous testing using conventional microbial testing, metagenomic next-generation sequencing, and nanopore targeted sequencing.
A total of 218 patients were included. Among the 168 cases of pulmonary infection, 246 strains of pathogens were confirmed. Nanopore targeted sequencing outperformed conventional microbial testing, identifying more pathogens with a sensitivity increase of 47.9% (77.2% vs. 29.3%). Metagenomic next-generation sequencing had a sensitivity of 82.9%. Total of 70.1% patients had consistent results in both metagenomic next-generation sequencing and nanopore targeted sequencing. Nanopore targeted sequencing exhibited significantly higher sensitivity in detecting Pneumocystis jiroveci, cytomegalovirus, Mycobacterium tuberculosis, Nontuberculous mycobacteria, Streptococcus pneumoniae, and Mycoplasma pneumoniae compared to conventional microbial testing. However, metagenomic next-generation sequencing demonstrated higher sensitivity than nanopore targeted sequencing for Aspergillus (88.5% vs. 53.8%). Regarding the detection of co-infections, nanopore targeted sequencing displayed significantly higher sensitivity than conventional microbial testing (76.7% vs. 28.7%) and was on par with metagenomic next-generation sequencing (76.7% vs. 82.9%).
Nanopore targeted sequencing performs equally well as metagenomic next-generation sequencing in bronchoalveolar lavage fluid for pathogen diagnosis in pneumonia, both methods showing higher sensitivity than conventional microbial testing. Nanopore targeted sequencing can be considered a reliable method for diagnosing pathogens in pneumonia.
评估纳米孔靶向测序在肺炎病原体诊断中的价值。
本大规模多中心前瞻性研究于 2022 年 4 月至 10 月在中国 8 家医院进行。纳入入院时诊断为肺炎的住院患者。收集完整的临床数据,并从每位患者获得支气管肺泡灌洗液。这些样本同时进行常规微生物检测、宏基因组下一代测序和纳米孔靶向测序。
共纳入 218 例患者。在 168 例肺部感染病例中,共确定了 246 株病原体。纳米孔靶向测序优于常规微生物检测,病原体检出率提高了 47.9%(77.2%比 29.3%)。宏基因组下一代测序的灵敏度为 82.9%。在宏基因组下一代测序和纳米孔靶向测序中,共有 70.1%的患者结果一致。与常规微生物检测相比,纳米孔靶向测序在检测卡氏肺孢子虫、巨细胞病毒、结核分枝杆菌、非结核分枝杆菌、肺炎链球菌和肺炎支原体方面具有更高的灵敏度。然而,宏基因组下一代测序在检测曲霉方面的灵敏度高于纳米孔靶向测序(88.5%比 53.8%)。在检测混合感染方面,纳米孔靶向测序的灵敏度显著高于常规微生物检测(76.7%比 28.7%),与宏基因组下一代测序相当(76.7%比 82.9%)。
纳米孔靶向测序与宏基因组下一代测序在肺炎患者支气管肺泡灌洗液病原体诊断中性能相当,两种方法的灵敏度均高于常规微生物检测。纳米孔靶向测序可作为肺炎病原体诊断的可靠方法。